CA2545443A1 - Solid amorphous dispersions of an mtp inhibitor for treatment of obesity - Google Patents

Solid amorphous dispersions of an mtp inhibitor for treatment of obesity Download PDF

Info

Publication number
CA2545443A1
CA2545443A1 CA002545443A CA2545443A CA2545443A1 CA 2545443 A1 CA2545443 A1 CA 2545443A1 CA 002545443 A CA002545443 A CA 002545443A CA 2545443 A CA2545443 A CA 2545443A CA 2545443 A1 CA2545443 A1 CA 2545443A1
Authority
CA
Canada
Prior art keywords
solid amorphous
dispersion
drug
amorphous dispersion
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002545443A
Other languages
English (en)
French (fr)
Inventor
Dwayne Thomas Friesen
Ravi Mysore Shanker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2545443A1 publication Critical patent/CA2545443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002545443A 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity Abandoned CA2545443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
US60/519,931 2003-11-14
PCT/IB2004/003581 WO2005046644A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Publications (1)

Publication Number Publication Date
CA2545443A1 true CA2545443A1 (en) 2005-05-26

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002545443A Abandoned CA2545443A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Country Status (16)

Country Link
US (1) US20080293801A1 (enExample)
EP (1) EP1696887A1 (enExample)
JP (1) JP2007511500A (enExample)
KR (1) KR20060096076A (enExample)
CN (1) CN1878538A (enExample)
AR (1) AR048206A1 (enExample)
AU (1) AU2004289110A1 (enExample)
BR (1) BRPI0416596A (enExample)
CA (1) CA2545443A1 (enExample)
CO (1) CO5690536A2 (enExample)
IL (1) IL175372A0 (enExample)
MX (1) MXPA06005489A (enExample)
NO (1) NO20062778L (enExample)
NZ (1) NZ546677A (enExample)
TW (1) TW200515909A (enExample)
WO (1) WO2005046644A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619989A2 (pt) * 2005-12-15 2011-10-25 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, métodos para o tratamento e/ou prevenção de enfermidades que estão associados com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
JP5711151B2 (ja) * 2010-01-06 2015-04-30 武田薬品工業株式会社 インドール誘導体
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
RS50712B (sr) * 2001-06-28 2010-06-30 Pfizer Products Inc. Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
NZ546677A (en) 2008-11-28
BRPI0416596A (pt) 2007-01-30
US20080293801A1 (en) 2008-11-27
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
AR048206A1 (es) 2006-04-12
NO20062778L (no) 2006-08-14
KR20060096076A (ko) 2006-09-05
CO5690536A2 (es) 2006-10-31
JP2007511500A (ja) 2007-05-10
IL175372A0 (en) 2006-09-05
AU2004289110A1 (en) 2005-05-26
WO2005046644A1 (en) 2005-05-26
CN1878538A (zh) 2006-12-13
TW200515909A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
TWI388324B (zh) 含有泊沙康唑（ｐｏｓａｃｏｎａｚｏｌｅ）之高密度組合物及包含該組合物之調配物
EP0901786B1 (en) Solid pharmaceutical dispersions with enhanced bioavailability
US9387252B2 (en) Pharmaceutical compositions with enhanced performance
US8372836B2 (en) Spray dried formulation
KR20120101439A (ko) 프로페인-1-설폰산 ｛3-〔5-(4-클로로-페닐)-1ｈ-피롤로〔2,3-ｂ〕피리딘-3-카보닐〕-2,4-다이플루오로-페닐｝-아마이드 조성물 및 그의 용도
KR20140107691A (ko) 의약 조성물
JP2003518038A (ja) 流動床噴霧乾燥によるナノ粒子製造方法
EP2083820A1 (en) Pharmaceutical compositions comprising intra- and extra- granular fractions
EP1741424B1 (en) Solid pharmaceutical dispersions with enhanced bioavailabilty
WO2001089574A1 (en) Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
WO2020136995A1 (ja) セルロース粉末、その使用および錠剤
CA2867701C (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
US20080293801A1 (en) Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
TWI724534B (zh) 纖維素粉末、錠劑及錠劑之製造方法
MX2007005427A (es) Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida.
EP4486303A1 (en) Enteric coated dry powdered cannabinoid formulations
US20090264476A1 (en) CB-1 receptor modulator formulations
HK1094533A (en) Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
CN113318097A (zh) 一种抗特发性肺纤维化的粉雾剂及制备方法
JPH04368330A (ja) ペミロラストカリウムの徐放性製剤
CN120617184A (zh) 一种高口服生物利用度氟苯尼考制剂制备方法
JP2022139962A (ja) 顆粒、顆粒の製造方法、及び錠剤
JPH0987190A (ja) 腎機能障害改善剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued